PHARMACEUTICAL SOLUTIONS

The COVID-19 crisis has taken  the planet  by storm and paralysed every industry like never before. This unforeseen situation has raised many  inquiries to  the pharma industry, making them  believe  their readiness to tackle such challenges  within the  future.  is that the  pharma capable of running continuous production  during a  critical time like these? How equipped are they  to take care of  or maybe  increase the output without compromising quality? How can the industry minimise human involvement in routine manufacturing operations? It’s about time the pharma industry  cares  AI  (AI).  the importance  of AI was never realised more before than now! Big pharma has already started adopting AI for drug design and development. AI  is additionally  getting used  in specific patient  education schemes  and for personalised medicines to facilitate treatment. Howe...

  Incidents of substandard or fraudulent pharmaceutical products  still  increase through what are assumed to be legitimate supply chains  round the  world. A recently released report by Organization for Economic Cooperation and Development (OECD)  and therefore the  european union   property  Office (EUIPO) estimates that international  trade  counterfeit pharmaceuticals reached USD 4.4 billion in 2016. These counterfeit medicines are believed to origin mostly in developing countries  which will  penetrate supply chains and make their  thanks to  anywhere  within the  world. This leaves regulators and distributors  during a  frenzy who struggle to locate substandard products that have entered the system. These potentially harmful products pose serious risk to the health of  many  patients who buy and consume these medicines believing that  they're  safe and effective. To a...

  Recent advancements in biologics have unleashed tremendous opportunities in addressing unmet medical needs taking healthcare to new heights. Biologics have shown promising  leads to  the treatment of debilitating conditions  like  diabetes, cancer, autoimmune diseases that affect millions worldwide. The success biologics  are often  attributed to their high specificity and enhanced therapeutic potential over conventional small molecules. It should come as no surprise then  that almost  80% of the novel drugs approved by the US FDA in 2020 constituted of biologics. Currently,  quite  800 peptide drugs are  within the  pipeline and around 197 peptide-based drugs  are  commercialised.  the worldwide  biologics market stood at an estimated USD 269,152 million in 2019 and  is predicted  to grow at a CAGR of 14.7%  to succeed in  up to USD 464,604 million by 2023. Asia-Pacific  espe...